Maria G. Cefalo
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: July 08, 2026
Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.
Journal: Translational oncology
Published: May 18, 2026
Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma.
Journal: Thyroid : official journal of the American Thyroid Association
Published: February 24, 2026
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.
Journal: Journal of hematology & oncology
Published: February 08, 2026
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: September 09, 2025
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.
Journal: Nature medicine
Published: August 19, 2025
Eye Salvage and Vision Preservation in High-Risk Intraocular Retinoblastoma Patients: Long-Term Results From the Prospective Phase II AIEOP RTB 012 Study.
Journal: Cancer medicine
Published: June 22, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: March 01, 2025
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.
Journal: Blood advances
Published: February 10, 2025
131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future.
Journal: ESMO open
Published: September 26, 2024
Last Updated: 09/26/2026